AIMS: Hepatitis C (HCV) infection is highly prevalent among injection drug users (IDUs) and likely to cause significant mortality over time, but little research attention has focused upon the magnitude of this risk, particularly among ageing users. This study examined trends over time in mortality attributed to liver disease, and in particular contrasting this with other more commonly studied causes of death [acquired immune deficiency syndrome (AIDS), suicide and overdose] among an ageing cohort of heroin-dependent people in Australia. DESIGN: Data linkage study of methadone treatment entrants with the National Deaths Index. SETTING: A cohort entering methadone treatment for heroin dependence in New South Wales, Australia, 1980-85. PARTICIPANTS: A total of 2489 people entering methadone treatment for heroin dependence and 54,847 person-years (PY) of follow-up. MEASUREMENTS: Linkage of data on all methadone entrants between 1980 and 1985 with data from the Australian National Deaths Index, linked using probabilistic record linkage software. FINDINGS: There were 8.2 deaths per 1000 PY [95% confidence interval (CI) 7.5-9.0], with standardized mortality ratios (SMRs) of 4.6 (95% CI 4.2-5.0). Almost one in five (17%) of deaths were from underlying liver-related causes, most commonly viral hepatitis. The overall mortality rate for any liver cause was 1.4 deaths per 1000 PY (95% CI 1.1-1.7), 17 times higher than to the general population (95% CI 13.4-21.3), with relative elevations more marked for females (SMR 27.9; 95% CI 17.7-41.9) than males (SMR 14.5; 95% CI 10.8-19.0). Liver mortality increased over time, becoming the most common cause of death by the end of follow-up. CONCLUSIONS: Liver disease has become the most common cause of mortality among ageing opioid-dependent people in an ageing Australian cohort. There is an imperative to reduce the long-term risks of HCV and other risks to the liver, including alcohol consumption, which are typically not the major clinical focus for this group.
AIMS: Hepatitis C (HCV) infection is highly prevalent among injection drug users (IDUs) and likely to cause significant mortality over time, but little research attention has focused upon the magnitude of this risk, particularly among ageing users. This study examined trends over time in mortality attributed to liver disease, and in particular contrasting this with other more commonly studied causes of death [acquired immune deficiency syndrome (AIDS), suicide and overdose] among an ageing cohort of heroin-dependent people in Australia. DESIGN: Data linkage study of methadone treatment entrants with the National Deaths Index. SETTING: A cohort entering methadone treatment for heroin dependence in New South Wales, Australia, 1980-85. PARTICIPANTS: A total of 2489 people entering methadone treatment for heroin dependence and 54,847 person-years (PY) of follow-up. MEASUREMENTS: Linkage of data on all methadone entrants between 1980 and 1985 with data from the Australian National Deaths Index, linked using probabilistic record linkage software. FINDINGS: There were 8.2 deaths per 1000 PY [95% confidence interval (CI) 7.5-9.0], with standardized mortality ratios (SMRs) of 4.6 (95% CI 4.2-5.0). Almost one in five (17%) of deaths were from underlying liver-related causes, most commonly viral hepatitis. The overall mortality rate for any liver cause was 1.4 deaths per 1000 PY (95% CI 1.1-1.7), 17 times higher than to the general population (95% CI 13.4-21.3), with relative elevations more marked for females (SMR 27.9; 95% CI 17.7-41.9) than males (SMR 14.5; 95% CI 10.8-19.0). Liver mortality increased over time, becoming the most common cause of death by the end of follow-up. CONCLUSIONS:Liver disease has become the most common cause of mortality among ageing opioid-dependent people in an ageing Australian cohort. There is an imperative to reduce the long-term risks of HCV and other risks to the liver, including alcohol consumption, which are typically not the major clinical focus for this group.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Fiona L Shand; Carolyn Day; William Rawlinson; Louisa Degenhardt; Nicholas G Martin; Elliot C Nelson Journal: Aust N Z J Public Health Date: 2014-04 Impact factor: 2.939
Authors: Gregory D Deans; Jesse D Raffa; Calvin Lai; Benedikt Fischer; Mel Krajden; Janaki Amin; Scott R Walter; Gregory J Dore; Jason Grebely; Mark W Tyndall Journal: CMAJ Open Date: 2013-05-23
Authors: Daniel Fuster; Kaku So-Armah; Debbie M Cheng; Sharon M Coleman; Natalia Gnatienko; Dmitry Lioznov; Evgeny M Krupitsky; Matthew S Freiberg; Jeffrey H Samet Journal: Curr HIV Res Date: 2021 Impact factor: 1.341